使用Nucleo CMP Forte™治疗腕管综合征患者的观察性初步研究。
Observational pilot study of patients with carpal tunnel syndrome treated with Nucleo CMP Forte™.
作者信息
Povedano M, Martínez Y, Tejado A, Arroyo P, Tebe C, Lorenzo J L, Montero J
机构信息
Servicio de Neurología y Neurofisiología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Unitat de Bioestadística (UBiDi), Institut d'Investigació Biomedica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
出版信息
Pain Manag. 2019 Mar 1;9(2):123-129. doi: 10.2217/pmt-2018-0050. Epub 2018 Nov 19.
AIM
Carpal tunnel syndrome (CTS) is a very common entrapment neuropathy characterized by pain and paresthesia in the territory of the median nerve. Although this syndrome has a considerable impact on the patient's quality of life, its medical treatment is far from optimal.
MATERIAL & METHODS: We performed an observational study to evaluate Nucleo CMP Forte in patients with electromyography-confirmed, mild-moderate CTS. Pain was assessed using a visual analog scale, electromyogram and the SF-36.
RESULTS
Pain decreased significantly after 6 months. Quality of life improved significantly in the pain dimensions. No significant differences were observed in electromyographic findings. No adverse events were reported.
CONCLUSIONS
Nucleotides could prove useful for the nonsurgical treatment of CTS. Further studies are necessary to confirm this.
目的
腕管综合征（CTS）是一种非常常见的卡压性神经病变，其特征为正中神经支配区域疼痛和感觉异常。尽管该综合征对患者生活质量有相当大的影响，但其药物治疗远非最佳。
材料与方法
我们进行了一项观察性研究，以评估强力核甘酸复合物（Nucleo CMP Forte）对肌电图确诊的轻中度腕管综合征患者的疗效。使用视觉模拟量表、肌电图和SF-36评估疼痛情况。
结果
6个月后疼痛显著减轻。生活质量在疼痛维度上有显著改善。肌电图检查结果未观察到显著差异。未报告不良事件。
结论
核苷酸可能被证明对腕管综合征的非手术治疗有用。需要进一步研究来证实这一点。
Zotero 插件